Baillie Gifford & Co. Purchases 6,826 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Baillie Gifford & Co. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,411 shares of the medical research company's stock after acquiring an additional 6,826 shares during the quarter. Baillie Gifford & Co. owned approximately 0.15% of Charles River Laboratories International worth $13,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in CRL. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Mizuho Securities USA LLC raised its position in shares of Charles River Laboratories International by 2,336.4% during the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock worth $19,081,000 after acquiring an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd raised its position in shares of Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock worth $49,573,000 after acquiring an additional 90,000 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James C. Foster bought 6,075 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CRL shares. CLSA downgraded Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $195.71.

Charles River Laboratories International Stock Up 0.5 %

Charles River Laboratories International stock traded up $0.86 during mid-day trading on Friday, reaching $163.11. The stock had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock's 50-day simple moving average is $172.84 and its 200-day simple moving average is $188.37. The firm has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).